Dr. Michelle Campbell is the Associate Director for Stakeholder Engagement and Clinical Outcomes in the Office of Neuroscience, Office of New Drugs (OND) in FDA’s Center for Drug Evaluation and Research. Dr. Campbell joined the FDA in 2014 and previously was a reviewer on the Clinical Outcome Assessments (COA) Staff and Scientific Coordinator of the COA Qualification Program in OND. Dr. Campbell’s focus is in patient-focused drug development and the use of patient experience data in the regulatory setting. Prior to joining FDA, Dr. Campbell spent more than 10 years conducting research in the academic-clinical setting, including five years in a neurology and developmental medicine department. Dr. Campbell earned her BA in Biology from the College of Notre Dame, her MS in Health Science from Towson University, and her PhD in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy.